Analysis
Attovia Therapeutics filed to raise up to $212.5 million in a US IPO, offering 12.5 million shares at an indicated range of $15 to $17 each and planning to list on the Nasdaq Global Market under the ticker ATTO. The San Carlos-based clinical-stage biopharmaceutical company develops biologics for immune-mediated diseases using its ATTOBODY platform, a biparatopic nanobody technology licensed from Alamar Biosciences.
The company's backing traces to a $105 million oversubscribed Series B in May 2024 led by Goldman Sachs Alternatives, which remains a shareholder alongside Deep Track Capital, Frazier Life Sciences, and venBio -- each holding at least a 5% stake heading into the offering. Its lead candidate, ATTO-1310, targets IL-31 for chronic pruritus and atopic dermatitis and has completed Phase 1 dosing in both healthy volunteers and patients, an early but real clinical data point.
Attovia's filing is one of several biotech IPOs moving through the pipeline this week alongside Reformation's consumer offering and GrubMarket's confidential food-tech filing, part of a broader reopening of the IPO window that's seen 210 IPOs price in 2026 through July 29 -- 7.14% ahead of the same point in 2025. For life sciences investors, an early-Phase-1 biotech going public at a $212.5 million raise size reflects continued investor appetite for clinical-stage biotech risk even without later-stage efficacy data, a window that tends to close quickly once market sentiment shifts.
